• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

羟乙基淀粉的研究。第二部分:450/0.7、450/0.5、450/0.3、300/0.4、200/0.7、200/0.5、200/0.3和200/0.1型羟乙基淀粉在志愿者血清和尿液中输注后的分子量分布变化

Studies on hydroxyethyl starch. Part II: Changes of the molecular weight distribution for hydroxyethyl starch types 450/0.7, 450/0.5, 450/0.3, 300/0.4, 200/0.7, 200/0.5, 200/0.3 and 200/0.1 after infusion in serum and urine of volunteers.

作者信息

Ferber H P, Nitsch E, Förster H

出版信息

Arzneimittelforschung. 1985;35(3):615-22.

PMID:2581591
Abstract

32 volunteers, none of whom showed any symptoms for kidney, liver or pancreas disease, were given by infusion 500 ml of various type of hydroxyethyl starch (HES) at a concentration of 6% (450/0.7, 450/0.5, 450/0.3, 300/0.4) as well as of 10% (200/0.7, 200/0.5, 200/0.3, 200/0.1) over a period of 30 min. After infusion both the Mw and the Mn diminished. The rate of elimination of HES from serum entirely depended on molar substitution and not on Mw. The quotient Mw/Mn decreased considerably over the entire test period. The lower molecular weight limit in serum remained relatively the same at 60,000 Daltons. Maximum molecular weight limit of urine, too, was 60,000 Daltons.

摘要

32名志愿者,均未表现出任何肾脏、肝脏或胰腺疾病症状,在30分钟内通过静脉输注给予500毫升不同类型的羟乙基淀粉(HES),浓度分别为6%(450/0.7、450/0.5、450/0.3、300/0.4)以及10%(200/0.7、200/0.5、200/0.3、200/0.1)。输注后,分子量(Mw)和数均分子量(Mn)均降低。HES从血清中的消除速率完全取决于摩尔取代度,而非分子量。在整个测试期间,Mw/Mn比值大幅下降。血清中的较低分子量极限相对保持在60,000道尔顿不变。尿液的最大分子量极限也是60,000道尔顿。

相似文献

1
Studies on hydroxyethyl starch. Part II: Changes of the molecular weight distribution for hydroxyethyl starch types 450/0.7, 450/0.5, 450/0.3, 300/0.4, 200/0.7, 200/0.5, 200/0.3 and 200/0.1 after infusion in serum and urine of volunteers.羟乙基淀粉的研究。第二部分:450/0.7、450/0.5、450/0.3、300/0.4、200/0.7、200/0.5、200/0.3和200/0.1型羟乙基淀粉在志愿者血清和尿液中输注后的分子量分布变化
Arzneimittelforschung. 1985;35(3):615-22.
2
[Evaluation of colloidal volume replacement solution 6% HES 40/0.5].
Anaesthesist. 1984 Feb;33(2):73-81.
3
[The in vivo molecular weight and renal threshold of hydroxyethyl starch in the example of molar substituted HES70/0/5].
Anasthesiol Intensivmed Notfallmed Schmerzther. 2001 Jan;36(1):31-7. doi: 10.1055/s-2001-10238.
4
[Mathematical decription of the human intravascular elimination of HAS after repeated infusions].
Infusionsther Klin Ernahr. 1979 Apr;6(2):119-22.
5
[Pharmacokinetics of middle-molecular hydroxyethyl starch (HAS 200/0,5].中分子羟乙基淀粉(HAS 200/0.5)的药代动力学
Infusionsther Klin Ernahr. 1980 Apr;7(2):96-102.
6
[The effect of molecular structure of hydroxyethyl starch on the elimination kinetics and fluidity of blood in human volunteers].
Arzneimittelforschung. 1993 Feb;43(2):99-105.
7
Studies on hydroxyethyl starch. Part I: Molecular characterization by size exclusion chromatography coupled with low-angle laser light scattering.羟乙基淀粉的研究。第一部分:尺寸排阻色谱结合低角度激光光散射的分子表征
Arzneimittelforschung. 1985;35(3):610-4.
8
[Effect of an infusion with middle molecular weight hydroxyethyl starch (HAES-steril 10%) on the flow properties of blood in healthy probands].
Infusionsther Klin Ernahr. 1981 Aug;8(4):200-4.
9
Rapidly degradable hydroxyethyl starch solutions impair blood coagulation after cardiac surgery: a prospective randomized trial.快速降解羟乙基淀粉溶液会损害心脏手术后的凝血功能:一项前瞻性随机试验。
Anesth Analg. 2009 Jan;108(1):30-6. doi: 10.1213/ane.0b013e31818c1282.
10
[Comparison of 2 6% middle-molecular hydroxyethyl starch solutions on elimination kinetics and flow characteristics of blood in volunteers].[两种6%中分子羟乙基淀粉溶液对志愿者血液清除动力学和血流特性的比较]
Infusionsther Transfusionsmed. 1994 Aug;21(4):251-9.

引用本文的文献

1
Changes in the degree of substitution of HES in vivo and their influence on methods for determining HES concentrations in plasma.体内 HES 取代度的变化及其对 HES 血浆浓度测定方法的影响。
PLoS One. 2023 Aug 22;18(8):e0290339. doi: 10.1371/journal.pone.0290339. eCollection 2023.
2
Assessment of Hydroxyethyl Starch (6% HES 130/0.4) Kidney Storage in Critically Ill Dogs: A Post-mortem Prospective Study.羟乙基淀粉(6% HES 130/0.4)在重症犬肾脏储存情况的评估:一项尸检前瞻性研究
Front Vet Sci. 2022 Jan 6;8:802507. doi: 10.3389/fvets.2021.802507. eCollection 2021.
3
Fluid resuscitation in sepsis: reexamining the paradigm.
脓毒症中的液体复苏:重新审视范式
Biomed Res Int. 2014;2014:984082. doi: 10.1155/2014/984082. Epub 2014 Aug 11.
4
Accumulation of hydroxyethyl starch in human and animal tissues: a systematic review.羟乙基淀粉在人和动物组织中的蓄积:一项系统评价。
Intensive Care Med. 2014 Feb;40(2):160-170. doi: 10.1007/s00134-013-3156-9. Epub 2013 Nov 21.
5
Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function.羟乙基淀粉(HES)与其他液体疗法:对肾功能的影响。
Cochrane Database Syst Rev. 2013 Jul 23;2013(7):CD007594. doi: 10.1002/14651858.CD007594.pub3.
6
Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: a meta-analysis of clinical studies.分子量和取代度对羟乙基淀粉组织摄取的影响:临床研究的荟萃分析。
Clin Pharmacokinet. 2012 Apr 1;51(4):225-36. doi: 10.2165/11594700-000000000-00000.
7
Pharmacokinetics and Tolerability of a New Hydroxyethyl Starch (HES) Specification [HES (130/0.4)] after Single-Dose Infusion of 6% or 10% Solutions in Healthy Volunteers.新型羟乙基淀粉(HES)规格[HES(130/0.4)]在健康志愿者中单次输注 6%或 10%溶液的药代动力学和耐受性。
Clin Drug Investig. 1998;16(2):151-60. doi: 10.2165/00044011-199816020-00008.
8
Pharmacokinetics of hydroxyethyl starch.羟乙基淀粉的药代动力学
Clin Pharmacokinet. 2005;44(7):681-99. doi: 10.2165/00003088-200544070-00002.
9
Mechanisms of postoperative prolonged plasma volume expansion with low molecular weight hydroxethy starch (HES 200/0.62, 6%).低分子量羟乙基淀粉(HES 200/0.62,6%)导致术后血浆容量长期扩张的机制
Intensive Care Med. 1995 Jul;21(7):577-83. doi: 10.1007/BF01700163.
10
Haemodilution therapy in ischaemic stroke: plasma concentrations and plasma viscosity during long-term infusion of dextran 40 or hydroxyethyl starch 200/0.5.
Eur J Clin Pharmacol. 1987;31(6):705-10. doi: 10.1007/BF00541299.